WILMINGTON, Del.--(BUSINESS WIRE)--Rigrodsky & Long, P.A.:
- Do you own shares of Derma Sciences, Inc. (NASDAQ CM: DSCI)?
- Did you purchase any of your shares prior to January 11, 2017?
- Do you think the proposed buyout price is too low?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Derma Sciences, Inc. (“Derma Sciences” or the “Company”) (NASDAQ CM: DSCI) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Integra LifeSciences Holdings Corporation (“Integra”) (NASDAQ GS: IART).
Click here to learn more: http://rigrodskylong.com/investigations/derma-sciences-inc-dsci-buyout.
Under the terms of the agreement, shareholders of Derma Sciences will receive $7.00 in cash for each share of Derma Sciences common stock.
The investigation concerns whether Derma Sciences’ board of directors failed to adequately shop the Company and obtain the best possible value for Derma Sciences shareholders before entering into an agreement with Integra.
If you own the common stock of Derma Sciences and purchased your shares before January 11, 2017, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to email@example.com, or at: http://rigrodskylong.com/investigations/derma-sciences-inc-dsci-buyout.
Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.
Attorney advertising. Prior results do not guarantee a similar outcome.